MGMT and glioblastoma: To test if EGFRvIII has an influence on TMZ sensitivity we retrospectively analyzed the overall survival of 336 patients with IDH1 wild type (wt) GBM and known MGMT promoter, EGFR amplification and EGFRvIIII status who had been treated with standard of care.